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to have calciﬁed lesions and more likely to have ACC/AHA Type C
lesions. The MACE rate was non-signiﬁcantly higher for patients
enrolled in a clinical trial versus not (12.6% versus 12.2%, p ¼ 0.8) as
was TVR (6.4% versus 5.6%, p ¼ 0.4). Patients enrolled in clinical trials
had a lower mortality after PCI (0.8% versus 4%, p < .001).
CONCLUSIONS Patients enrolled in clinical trials had a lower mor-
tality rate after PCI than those that were not. Whether this difference
is due to a lower risk proﬁle of this cohort, or the beneﬁts associated
with trial enrollment, including closer follow-up, warrants further
investigation.
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BACKGROUND Clinical trials in the United States tend to enroll
racially homogenous cohorts, thereby limiting generalizability. We
sought to identify correlates of clinical trial enrollment from a large
and racially diverse PCI registry.
METHODS We conducted a single-center study of patients undergoing
PCI between 1/1/2010 and 12/31/2013 (n¼14,075) at the Mount Sinai
Medical Center. We compared demographic, clinical and procedural
characteristics between patients who were and were not enrolled in
clinical trials during this period. Independent correlates of trial
enrollment were identiﬁed using multivariable logistic regression.
RESULTS Patients enrolled in trials (n¼659, 4.69%) were younger and
more likely to present with stable clinical syndromes compared to
their counterparts not enrolled (n¼13,416, 95.32%). African-Americans
and Hispanics were more frequently enrolled while Asians were less
likely to enter trials compared to Caucasians. In terms of PCI proce-
dural characteristics, the enrolled cohort was less likely to undergo
PCI of a saphenous vein graft and have thrombotic lesions (Table).Table. Baseline and procedural characteristics of patients enrolled in clinical trials versus not at Mount Sinai
Hospital, New York.p value Odds ratio95% Conﬁdence
IntervalAge 0.001 0.98 0.97-0.99Hispanics 0.042 1.32 1.01-1.73Prior MI 0.046 0.74 0.55-0.99Dialysis 0.015 0.23 0.07-0.76STEMI 0.005 0.16 0.04-0.57PCI-SVG 0.018 0.09 0.01-0.66Thrombosis 0.011 1.98 1.17-3.36MI: Myocardial Infarction; PCI-SVG: Percutaneous Coronary Intervention- Saphenous Vein Graft; STEMI: ST-
Segment Elevation Myocardial Infarction
CONCLUSIONS Patients enrolled in clinical trials differ substantially
from those not enrolled in terms of their baseline demographics,
clinical presentation, and procedural parameters, highlighting the
limited generalizability of trial results to real-world populations.
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BACKGROUND The 2-stenting technique has been regarded to show
worse clinical outcomes than the 1-stenting technique after bifurca-
tion PCI with 1st generation DES. However, there has been paucity of
data comparing 1- and 2-stenting techniques with the use of 2nd
generation DES. Therefore, we sought to investigate the differential
clinical outcomes after PCI for coronary bifurcation lesions with 1- or
2-stenting techniques using 1st or 2nd generation drug-eluting stent
(DES).
METHODS Patient-level pooled analysis was performed with 3,162
patients undergoing PCI using 1st or 2nd generation DES for bifurca-
tion lesions from the ’Korean Bifurcation Pooled Cohorts’ (COBIS II,
EXCELLENT, and RESOLUTE-Korea registry). The 3-year clinical out-
comes were compared between 1- and 2-stenting techniques, strati-
ﬁed by the type of DES.
RESULTS With 1st generation DES, rates of target lesion failure (TLF)
or patient-oriented composite outcome (POCO, a composite of all
death, any MI, any repeat revascularization, and cerebrovascular ac-
cidents) at 3-year were signiﬁcantly higher after 2-stenting than 1-
stenting technique (TLF: 8.6% vs. 17.5%, p<0.001; POCO 18.1% vs.
28.5%, p<0.001). With 2nd generation DES, however, there was no
difference between 1- and 2-stenting techniques (TLF: 5.4% vs. 5.8%,
p¼0.768; POCO: 11.2% vs. 12.9%, p¼0.995). The differential impacts of
2-stenting technique on the prognosis according to the type of DES
were also corroborated with similar results by the inverse probability
weighted model. The 2-stenting technique was a signiﬁcant inde-
pendent predictor of TLF in 1st generation DES (HR 2.046, 95% CI
1.114-3.759, p<0.001), but not in 2nd generation DES (HR 0.667, 95%
CI 0.247-1.802, p¼0.425).
